HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M400205-MCP200v1 4/4/555    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moreira, J. M. A. Articles by Celis, J. E. Search for Related Content PubMed PubMed Citation Articles by Moreira, J. M. A. Articles by Celis, J. E. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 4:555-569, 2005.
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Down-regulation of the Tumor Suppressor Protein 14-3-3 Is a Sporadic Event in Cancer of the Breast

José M. A. Moreira^,, Gita Ohlsson, Fritz E. Rank^¶ and Julio E. Celis^,||

From the Department of Proteomics in Cancer, Institute of Cancer Biology and Danish Centre for Translational Breast Cancer Research, Danish Cancer Society, DK-2100 Copenhagen and the ^¶ Department of Pathology, The Centre of Diagnostic Investigations, Copenhagen University, Hospital, DK-2100 Copenhagen, Denmark

14-3-3 proteins comprise a family of highly conserved and broadly expressed multifunctional regulatory proteins that are involved in various cellular processes such as cell cycle progression, cell growth, differentiation, and apoptosis. Transcriptional expression of the isoform of 14-3-3 is frequently impaired in human cancers, including carcinomas of the breast, which has led to the suggestion that this protein might be involved in the neoplastic transformation of breast epithelial cells. Here we report on the analysis of 14-3-3 expression in primary breast tumors using a proteomic approach complemented by immunohistochemical analysis by means of specific antibodies against this isoform. We show that the levels of expression of 14-3-3 were similar in non-malignant breast epithelial tissue and matched malignant tissue with only sporadic loss of expression observed in 3 of the 68 tumors examined. Moreover we show that 14-3-3 immunoreactivity was restricted to epithelial cells and significantly stronger in the myoepithelial cells that line the mammary ducts and lobules. The lack of expression of 14-3-3 in the three breast carcinomas was not associated with high levels of expression of the dominant-negative transcriptional regulator Np63 or with increased expression of estrogen-responsive finger protein, a ubiquitin-protein ligase (E3) that targets 14-3-3 for proteolysis. Validation of the results was performed retrospectively on an independent clinical tumor sample set using a tissue microarray containing 65 primary tumors. Our data suggest that, contrary to what was previously thought, loss of expression of 14-3-3 protein is not a frequent event in breast tumorigenesis.

^|| To whom correspondence may be addressed: Dept. of Proteomics in Cancer, Inst. of Cancer Biology and Danish Centre for Translational Breast Cancer Research (DCTB), Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen, Denmark. Tel.: 45-35257500; Fax: 45-35257721; E-mail: jec{at}cancer.dk

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. E. Celis, P. Gromov, T. Cabezon, J. M. A. Moreira, E. Friis, K. Jirstrom, A. Llombart-Bosch, V. Timmermans-Wielenga, F. Rank, and I. Gromova 15-Prostaglandin Dehydrogenase Expression Alone or in Combination with ACSM1 Defines a Subgroup of the Apocrine Molecular Subtype of Breast Carcinoma Mol. Cell. Proteomics, October 1, 2008; 7(10): 1795 - 1809. [Abstract] [Full Text] [PDF]

				N. Dumont, M. B. Wilson, Y. G. Crawford, P. A. Reynolds, M. Sigaroudinia, and T. D. Tlsty Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers PNAS, September 30, 2008; 105(39): 14867 - 14872. [Abstract] [Full Text] [PDF]

				J. M. A. Moreira, T. Shen, G. Ohlsson, P. Gromov, I. Gromova, and J. E. Celis A Combined Proteome and Ultrastructural Localization Analysis of 14-3-3 Proteins in Transformed Human Amnion (AMA) Cells: Definition of A Framework to Study Isoform-Specific Differences Mol. Cell. Proteomics, July 1, 2008; 7(7): 1225 - 1240. [Abstract] [Full Text] [PDF]

				F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]

				B. Han, H. Xie, Q. Chen, and J.-T. Zhang Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3{sigma}. Mol. Cancer Ther., April 1, 2006; 5(4): 903 - 912. [Abstract] [Full Text] [PDF]

				Y. Liu, H. Liu, B. Han, and J.-T. Zhang Identification of 14-3-3{sigma} as a Contributor to Drug Resistance in Human Breast Cancer Cells Using Functional Proteomic Analysis. Cancer Res., March 15, 2006; 66(6): 3248 - 3255. [Abstract] [Full Text] [PDF]

				T. Suzuki, T. Urano, T. Tsukui, K. Horie-Inoue, T. Moriya, T. Ishida, M. Muramatsu, Y. Ouchi, H. Sasano, and S. Inoue Estrogen-Responsive Finger Protein as a New Potential Biomarker for Breast Cancer Clin. Cancer Res., September 1, 2005; 11(17): 6148 - 6154. [Abstract] [Full Text] [PDF]